Drug Res (Stuttg) 2023; 73(03): 170-174
DOI: 10.1055/a-1977-8848
Original Article

MicroRNA-32 Suppression: its Effects on Prostate Cancer Cells’ Capability to Proliferate and Migrate

Farah A. Al-Marzook
1   College of Medical and Health Technologies, Al-Zahraa University for Women, Karbala, Iraq
,
Duha Maithem Hassan
1   College of Medical and Health Technologies, Al-Zahraa University for Women, Karbala, Iraq
,
Maha Waleed Alghazal
2   Al-Rafidain University College, Dentistry department, Baghdad, Iraq
,
Rana Abd Alameer Kadheem
3   College of Pharmacy, National University of Science and Technology, Dhi-Qar, Iraq
,
Abduladheem Turki Jalil
4   Medical Laboratories Techniques Department, Al-Mustaqbal University College, Babylon, Hilla, Iraq
,
Marwan Mahmood Saleh
5   Department of Biophysics, College of Applied Sciences, University of Anbar, Ramadi, Iraq
6   Medical Laboratory Technology Department, College of Medical Technology, The Islamic University, Najaf, Iraq
› Author Affiliations

Abstract

Introduction This paper sought to scrutinize the role of microRNA-32 (miR-32) on the growth and migration as well as on the expression of metastatic genes in PC3 cells of prostate cancer in vitro.

Methods Subsequent transfection of cells with miR-32 mimics, miR-32 inhibitor, negative control (NC), cell proliferation using MTT, and apoptosis by ELISA were performed. Furthermore, qRT-PCR was directed to measure the expression levels of matrix metalloproteinase 2 (MMP2) and vascular endothelial growth factors (VEGF) as metastatic and angiogenesis genes in the progression of PC3.

Results miR-32 was overexpressed in PC3 cells compared to normal cells (P<0.001). Down-regulation of miR-32 obstructs in vitro proliferation and migration while intensifying the apoptosis rate in PC3 cells. Also, we found that miR-32 negatively modulates the expression of VEGF and MMP2 in PC3 cells.

Conclusion These results indicate that the suppression of miR-32 might offer an auxiliary treatment procedure for addressing the invasion, progression, and metastasis in PCa patients by improving cell apoptosis.



Publication History

Received: 18 October 2022

Accepted: 07 November 2022

Article published online:
10 January 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany